RxDoctor Payments Data

Youssef Siage, MD

Internal Medicine · Charlotte, NCNPI 1346386190

Payments from drug & device makers

$247in general payments, 2019–2025

Across 14 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$78
  • Regeneron Healthcare Solutions, Inc.$38
  • Abbott$25
  • Exact Sciences$22
  • GSK$20
  • Bayer$20
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$16366%
  • Education$8434%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$247 in reported general payments places this provider in the 55th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$90,476
Medicare patients
215
Services billed
1,333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$68,851
EliquisApixaban57$64,546
TrulicityDulaglutide32$63,297
MounjaroTirzepatide46$48,217
LinzessLinaclotide28$32,107
JanuviaSitagliptin Phosphate19$31,289
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$30,938
XareltoRivaroxaban33$30,093
Tresiba Flextouch U-200Insulin Degludec16$24,998
JardianceEmpagliflozin11$19,270
FarxigaDapagliflozin Propanediol12$14,497
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$10,943
Lantus SolostarInsulin Glargine,hum.Rec.Anlog84$10,822
Breo ElliptaFluticasone/Vilanterol17$9,745
MyrbetriqMirabegron14$7,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$12$111,51478 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$20$47,33576 claims
AbbVieLinzess, Synthroid$18$33,86044 claims
Boehringer IngelheimJardiance, Stiolto Respimat$15$30,21326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →